Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large, diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the United States, Chile, and Peru has not been known. METHODS: In this ongoing, double-blind, randomized, placebo-controlled, phase 3 clinical trial, we investigated the safety, vaccine efficacy, and immunogenicity of two doses of AZD1222 as compared with placebo in preventing the onset of symptomatic and severe coronavirus disease 2019 (Covid-19) 15 days or more after the second dose in adults, including older adults, in the United States, Chile, and Peru. RESULTS: A total of 32,451 participants underwent randomization, in a 2:1 ratio, to receive AZD1222 (21,635 participants) or placebo (10,816 participants). AZD1222 was safe, with low incidences of serious and medically attended adverse events and adverse events of special interest; the incidences were similar to those observed in the placebo group. Solicited local and systemic reactions were generally mild or moderate in both groups. Overall estimated vaccine efficacy was 74.0% (95% confidence interval [CI], 65.3 to 80.5; P<0.001) and estimated vaccine efficacy was 83.5% (95% CI, 54.2 to 94.1) in participants 65 years of age or older. High vaccine efficacy was consistent across a range of demographic subgroups. In the fully vaccinated analysis subgroup, no severe or critical symptomatic Covid-19 cases were observed among the 17,662 participants in the AZD1222 group; 8 cases were noted among the 8550 participants in the placebo group (<0.1%). The estimated vaccine efficacy for preventing SARS-CoV-2 infection (nucleocapsid antibody seroconversion) was 64.3% (95% CI, 56.1 to 71.0; P<0.001). SARS-CoV-2 spike protein binding and neutralizing antibodies increased after the first dose and increased further when measured 28 days after the second dose. CONCLUSIONS: AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults. (Funded by AstraZeneca and others; ClinicalTrials.gov number, NCT04516746.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Modified Poisson Regression Approach to Prospective Studies with Binary Data
Zou, G. (2004) · American Journal of Epidemiology · doi:10.1093/aje/kwh090 · Cited by 9,615
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259
Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citationEfficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102214 · Cited by 1,257
Self-citationMadhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Self-citationVoysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00432-3 · Cited by 1,119
Self-citation
Research works printed but not linked: 1
- COVID-19 Vaccine Tracker. Oxford/AstraZeneca: AZD1222. 2021 (https://covid19.trackvaccines.org/vaccines/4/).
Cited by
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Dunkle, L. M., Kotloff, K. L., Gay, C. L., Áñez, G., Adelglass, J. M., Barrat Hernández, A. Q., Harper, W. L., Duncanson, D. M., McArthur, M. A., Florescu, D. F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116185 · Cited by 443
Self-citationTrajectory of long covid symptoms after covid-19 vaccination: community based cohort study
Ayoubkhani, D., Bermingham, C., Pouwels, K. B., Glickman, M., Nafilyan, V., Zaccardi, F., Khunti, K., Alwan, N. A., & Walker, A. S. (2022) · BMJ · doi:10.1136/bmj-2021-069676 · Cited by 414
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00915-3 · Cited by 341
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310
Nordström, P., Ballin, M., & Nordström, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00089-7 · Cited by 302
Nordström, P., Ballin, M., & Nordström, A. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00143-8 · Cited by 250
Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
Dai, L., Gao, L., Tao, L., Hadinegoro, S. R., Erkin, M., Ying, Z., He, P., Girsang, R. T., Vergara, H., Akram, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202261 · Cited by 250
Chi, W.-Y., Li, Y.-D., Huang, H.-C., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C.-F., & Wu, T.-C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 215
“0% overall efficacy and 100% protection from severe COVID-19 illness [25].”
BackgroundRahmani, K., Shavaleh, R., Forouhi, M., Disfani, H. F., Kamandi, M., Oskooi, R. K., Foogerdi, M., Soltani, M., Rahchamani, M., Mohaddespour, M., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.873596 · Cited by 204
“The results supported the findings of phase 3 of the clinical trials on the effectiveness of BNT162b2 mRNA, mRNA1273, and ChAdOx1 vaccines (12, 83, 84).”
ResultCOVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B., Wörmann, B., Turajlic, S., & von Lilienfeld-Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 204
Kumari, M., Lu, R., Li, M., Huang, J., Hsu, F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00852-9 · Cited by 178
“In two Phase III trials, the overall vaccine efficacy in individuals receiving two standard doses was reported to be ~ 70% [43, 44].”
BackgroundCOVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
Pillay, J., Bialy, L., Gaudet, L., Wingert, A., Mackie, A. S., Paterson, D. I., & Hartling, L. (2022) · BMJ · doi:10.1136/bmj-2021-069445 · Cited by 164
Madhavan, M., Ritchie, A. J., Aboagye, J., Jenkin, D., Provstgaard-Morys, S., Tarbet, I., Woods, D., Davies, S., Baker, M., Platt, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104298 · Cited by 149
Self-citationAu, W. Y., & Cheung, P. P.-H. (2022) · BMJ · doi:10.1136/bmj-2022-069989 · Cited by 143
Two centuries of vaccination: historical and conceptual approach and future perspectives
Montero, D. A., Vidal, R. M., Velasco, J., Carreño, L. J., Torres, J. P., O., M. A. B., Tovar-Rosero, Y.-Y., Oñate, A. A., & O’Ryan, M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326154 · Cited by 220
Follmann, D. A., Janes, H., Buhule, O. D., Zhou, H., Girard, B., Marks, K., Kotloff, K. L., Desjardins, M., Corey, L., Neuzil, K. M., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-1300 · Cited by 134
Self-citationYang, Z.-R., Jiang, Y.-W., Li, F.-X., Liu, D., Lin, T.-F., Zhao, Z.-Y., Wei, C., Jin, Q.-Y., Li, X.-M., Jia, Y.-X., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00390-1 · Cited by 138
“S SII-ChAdOx1 mRNA-1273 mRNA-1273 mRNA-1273 927/88 387 39/28 688 13/3248 10/12 713 16/12 727 644/40 629 41/2692 104/17 662 498/19 113 1/1162 244/19 070 214/14 287 9/2644 21/2139 1395/62 334 54/15 763 33/3041 10/6361 11/6361 817/30 512 42/2751 105/8550 669/18 924 1/287 524/16 059 498/14 164 10/853 16/1042 44·5 (27·8 to…”
InfluentialHigdon, M. M., Wahl, B., Jones, C. B., Rosen, J. G., Truelove, S. A., Baidya, A., Nande, A. A., ShamaeiZadeh, P. A., Walter, K. K., Feikin, D. R., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac138 · Cited by 133
High Rate of Asymptomatic Carriage Associated with Variant Strain OmicronPreprint
Garrett, N., Tapley, A., Andriesen, J. G., Seocharan, I., Fisher, L. H., Bunts, L., Espy, N., Wallis, C. L., Randhawa, A. K., Ketter, N., et al. (2021) · medRxiv · doi:10.1101/2021.12.20.21268130 · Cited by 125
Self-citationPrevention and Treatment Strategies for Respiratory Syncytial Virus (RSV)
Gatt, D., Martin, I., AlFouzan, R., & Moraes, T. J. (2023) · Pathogens · doi:10.3390/pathogens12020154 · Cited by 146
“In the recent SARS-COV-2 pandemic, adenovirus-based vaccines have demonstrated a good efficacy against severe disease [98] lending support to the argument that similar strategies for RSV may be successful, though concerns have arisen regarding an increased risk of thrombo-embolic events [99,100].”
BackgroundRecent developments in the immunopathology of COVID ‐19
Zhang, H., Sun, Y., Wang, Y., Yazıcı, D., Azkur, D., Öğülür, İ., Azkur, A. K., Yang, Z., Chen, X., Zhang, A., et al. (2022) · Allergy · doi:10.1111/all.15593 · Cited by 125
Lundberg, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023) · BMJ · doi:10.1136/bmj-2023-076990 · Cited by 121
Viral Vector Vaccine Development and Application during the COVID-19 Pandemic
Deng, S., Liang, H., Pin, C., Li, Y., Li, Z., Fan, S., Wu, K., Li, X., Chen, W., Qin, Y., et al. (2022) · Microorganisms · doi:10.3390/microorganisms10071450 · Cited by 133
“4% and a maximum of 90% in phase-III clinical testing covering 24,000 people [59].”
BackgroundBravo, L., Smolenov, I., Han, H. H., Li, P., Hosain, R., Rockhold, F., Clemens, S. A. C., Roa, C., Borja-Tabora, C., Quinsaat, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00055-1 · Cited by 106
Fusco, M. D., Lin, J., Vaghela, S., Lingohr-Smith, M., Nguyen, J. L., Sforzolini, T. S., Judy, J., Cane, A. D., & Moran, M. M. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2035222 · Cited by 116
“Such findings from real-world studies are generally consistent with the efficacy results of the randomized clinical trials (RCTs) of these vaccines [4-7].”
MethodResultBeladiya, J., Kumar, A., Vasava, Y., Parmar, K., Patel, D., Patel, S., Dholakia, S., Sheth, D., Boddu, S. H. S., & Patel, C. (2024) · Reviews in Medical Virology · doi:10.1002/rmv.2507 · Cited by 96
Kanokudom, S., Assawakosri, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10010086 · Cited by 91
“5 mL) contains 5×1010 infectious units [16].”
Arregocés-Castillo, L., Fernández-Niño, J. A., Rojas-Botero, M. L., Palacios-Clavijo, A. F., Pedraza, M. G., Rincón-Medrano, L., Pinto-Álvarez, M., Gómez, F. R., & Valdivia, B. T. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00035-6 · Cited by 97
Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status
Chavda, V. P., Bezbaruah, R., Valu, D., Patel, B., Kumar, A., Prasad, S., Kakoti, B. B., Kaushik, A. K., & Jesawadawala, M. (2023) · Vaccines · doi:10.3390/vaccines11020432 · Cited by 105
Liu, H., Wei, P., Kappler, J. W., Marrack, P., & Zhang, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825256 · Cited by 98
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Suah, J. L., Husin, M., Tok, P. S. K., Tng, B. H., Thevananthan, T., Low, E. V., Appannan, M. R., Muhamad Zin, F., Mohd Zin, S., Yahaya, H., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.028 · Cited by 76
“…http://creativecommons.org/licenses/by-nc-nd/4.0/ ) I T s e e ( a H 4 ( v a ( H u u f f h 1 l NTRODUCTION Since early 2021, clinical trials ( Falsey et al., 2021 ; anriover et al., 2021 ; Thomas et al., 2021 ) and real-world tudies on vaccine effectiveness ( Jara et al., 2021 ; Lopez Bernal…”
InfluentialXu, K., Wang, Z., Qin, M., Gao, Y., Luo, N., Xie, W., Zou, Y., Wang, J., & Ma, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1113156 · Cited by 100
“Clinical trials have shown COVID-19 vaccines to be immunogenic against SARS-CoV-2 infection and safe, with their efficacy ranging from 86% and 95% for the messenger RNA (mRNA) vaccines BNT162b2 (19) and mRNA-1273 (20), respectively, to 74% for the AZD1222 (ChAdOx1 nCoV-19) vaccine (21) in those aged 18 years and older.”
BackgroundTracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 97
“Another phase III clinical trial [NCT04516746] funded by AstraZeneca and others was conducted by Falsey et al..(37) They inspected the safety, effectiveness, and immunogenic potential of two dose regimes of AZD1222 vaccine in blocking the commencement of symptomatic and severe COVID-19 within 15 days or more following…”
BackgroundThe immune response to SARS-CoV-2 in people with HIV
Höft, M. A., Burgers, W. A., & Riou, C. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01087-w · Cited by 93
“S/Janssen vaccine ef fi cacy [121 – 123, 125, 126], with other major vaccine trials excluding or not reporting numbers of PWH.”
BackgroundReplicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena
Chavda, V. P., Bezbaruah, R., Athalye, M., Parikh, P. K., Chhipa, A. S., Patel, S. S., & Apostolopoulos, V. (2022) · Viruses · doi:10.3390/v14040759 · Cited by 71
“From them, Ad26COVS1 (Janssen/Johnson & Johnson), Vaxzevria (Oxford/AstraZeneca), and Covishield (Oxford/AstraZeneca formulation) have been approved by WHO and have displayed safety and efficacy against severe critical diseased conditions [71,77,96].”
BackgroundA systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Zhang, M., Liang, Y., Yu, D., Du, B., Cheng, W., Li, L., Yu, Z., Luo, S., Zhang, Y., Wang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.68973 · Cited by 72
Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study
Lee, J. E., Hwang, M., Kim, Y., Chung, M. J., Sim, B. H., Chae, K. J., Yoo, J. Y., & Jeong, Y. J. (2022) · Radiology · doi:10.1148/radiol.213072 · Cited by 68
“Nausea or vomiting 15 (5) 41 (18) 41 (19) 97 (13)”
Adenovirus-based vaccines—a platform for pandemic preparedness against emerging viral pathogens
Coughlan, L., Kremer, E. J., & Shayakhmetov, D. M. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.034 · Cited by 71
Cytokine Responses to Adenovirus and Adenovirus Vectors
Atasheva, S., & Shayakhmetov, D. M. (2022) · Viruses · doi:10.3390/v14050888 · Cited by 75
“To date, adenovirus-vectored vaccines against SARS-CoV-2 based on HAdV-D26 (Janssen Vaccines, Johnson & Johnson, New Brunswick, New Jersey, United States) [11], ChAdOx1 (Astra-Zeneca, Oxford, United Kingdom) [24], HAdV-D26/HAdV-C5 (Sputnik V vaccine Gamaleya Research Institute of Epidemiology and Microbiology, Moscow,…”
BackgroundPopa, A. D., Enache, A. I., Popa, I. V., Antoniu, S. A., Dragomir, R. A., & Burlacu, A. (2022) · Vaccines · doi:10.3390/vaccines10050672 · Cited by 70
“vaccines offered moderate protection (66% and, respectively, 55–81%) [6,7].”
BackgroundBoosting immunity to COVID-19 vaccines
Juno, J. A., & Wheatley, A. K. (2021) · Nature Medicine · doi:10.1038/s41591-021-01560-x · Cited by 62
Hertel, M., Heiland, M., Nahles, S., von Laffert, M., Mura, C., Bourne, P. E., Preißner, R., & Preißner, S. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18184 · Cited by 68
Rappaport, A. R., Hong, S.-J., Scallan, C. D., Gitlin, L., Akoopie, A., Boucher, G. R., Egorova, M., Espinosa, J. A., Fidanza, M., Kachura, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31005-z · Cited by 57
Nordström, P., Ballin, M., & Nordström, A. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3949410 · Cited by 58
Soegiarto, G., Wulandari, L., Purnomosari, D., Fahmita, K. D., Gautama, H. I., Hadmoko, S. T., Prasetyo, M. E., Mahdi, B. A., Arafah, N., Prasetyaningtyas, D., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.059 · Cited by 66
Kang, Y., Sun, C., Sun, J., Xie, C., Zhuang, Z., Xu, H.-Q., Liu, Z., Liu, Y., Peng, S., Yuan, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30222-w · Cited by 60
Severity of COVID-19 after Vaccination among Hemodialysis Patients: An Observational Cohort Study
Ashby, D. R., Caplin, B., Corbett, R., Asgari, E., Kumar, N., Sarnowski, A., Hull, R., Makanjuola, D., Cole, N. I., Chen, J., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.16621221 · Cited by 59
A cross-country comparison of Covid-19 containment measures and their effects on the epidemic curves
Cascini, F., Failla, G., Gobbi, C., Pallini, E., Jin, H., Luxi, W., Villani, L., Quentin, W., Boccia, S., & Ricciardi, W. (2022) · BMC Public Health · doi:10.1186/s12889-022-14088-7 · Cited by 74
Covid-19: virology, variants, and vaccines
Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 64
Advances in mRNA therapeutics for cancer immunotherapy: From modification to delivery
Han, G., Noh, D., Lee, H., Lee, S., Kim, S., Yoon, H. Y., & Hyeon, L. S. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114973 · Cited by 56
Will the COVID-19 pandemic end with the Delta and Omicron variants?
Wang, C., & Han, J. (2022) · Environmental Chemistry Letters · doi:10.1007/s10311-021-01369-7 · Cited by 54
Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn
Shahgolzari, M., Yavari, A., Arjeini, Y., Miri, S. M., Darabi, A., Nejad, A. S. M., & Keshavarz, M. (2021) · Gene Reports · doi:10.1016/j.genrep.2021.101417 · Cited by 55
Solante, R., Álvarez, C., Burhan, E., Chariyalertsak, S., Chiu, N., Chuenkitmongkol, S., Dung, D. V., Hwang, K., Ibarra, J. O., Kiertiburanakul, S., et al. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2143347 · Cited by 54
Cao, L., Lou, J., Chan, S. Y., Zheng, H., Liu, C., Zhao, S., Li, Q., Mok, C. K. P., Chan, R. W. Y., Chong, M. K. C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01877-1 · Cited by 49
Ryan, F. J., Norton, T. S., McCafferty, C., Blake, S. J., Stevens, N. E., James, J., Eden, G. L., Tee, Y. C., Benson, S. C., Masavuli, M. G., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100971 · Cited by 63
“…ChAdOx1-S (Oxford-AstraZe-neca), and mRNA-1273 (Moderna) vaccines are highly effective at preventing severe coronavirus disease 2019 (COVID-19), 1–3 although protection against infection wanes within 4–6 months after the second dose and two doses provide decreased protection against infection…”
van Doremalen, N., Schulz, J. E., Adney, D. R., Saturday, T. A., Fischer, R. J., Yinda, C. K., Thakur, N., Newman, J., Ulaszewska, M., Belij‐Rammerstorfer, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32248-6 · Cited by 42
Caronna, E., van den Hoek, T. C., Bolay, H., García‐Azorín, D., Gago‐Veiga, A. B., Valeriani, M., Takizawa, T., Meßlinger, K., Shapiro, R. E., Goadsby, P. J., et al. (2023) · Cephalalgia · doi:10.1177/03331024221131337 · Cited by 49
Song, J. Y., Choi, W. S., Heo, J. Y., Kim, E. J., Lee, J. S., Jung, D. S., Kim, S., Park, K., Eom, J. S., Jeong, S. J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102140 · Cited by 55
Mahroum, N., Lavine, N., Ohayon, A., Seida, R., Alwani, A., Alrais, M., Zoubi, M., & Bragazzi, N. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.872683 · Cited by 56
PICK-ing Malaysia’s Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio
Suah, J. L., Tok, P. S. K., Ong, S. M., Husin, M., Tng, B. H., Sivasampu, S., Thevananthan, T., Appannan, M. R., Zin, F. M., Zin, S. M., et al. (2021) · Vaccines · doi:10.3390/vaccines9121381 · Cited by 53
“0% against symptomatic COVID-19 [8], while for the BNT162b2 (Pfizer-BioNTech) vaccine, efficacy measured 91.”
BackgroundDurability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe, A., Pace, M. J., Bittaye, M., Tipoe, T., Adele, S., Alagaratnam, J., Aley, P. K., Ansari, M. A., Bara, A., Broadhead, S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157031 · Cited by 62
“However recent data from 325 the USA, Chile and Peru show no significant impact of gender or ethnicity on efficacy 326 of the AZD1222 vaccine [44].”
Caring for older adults during the COVID-19 pandemic
Prendki, V., Tiseo, G., & Falcone, M. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.02.040 · Cited by 27
Poustforoosh, A., Hashemipour, H., Tüzün, B., Azadpour, M., Faramarz, S., Pardakhty, A., Mehrabani, M., & Nematollahi, M. H. (2022) · Current Microbiology · doi:10.1007/s00284-022-02921-6 · Cited by 46
Rafati, A., Pasebani, Y., Jameie, M., Yang, Y., Jameie, M., Ilkhani, S., Amanollahi, M., Sakhaei, D., Rahimlou, M., & Kheradmand, A. (2023) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2023.0160 · Cited by 45
Broad-spectrum pan-genus and pan-family virus vaccines
Tan, C. W., Valkenburg, S., Poon, L. L. M., & Wang, L. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.05.017 · Cited by 44
New-onset IgA nephropathy following COVID-19 vaccination
Ma, Y., & Xu, G. (2022) · QJM · doi:10.1093/qjmed/hcac185 · Cited by 46
Saha, A., Roy, S. G., Dwivedi, R., Tripathi, P., Kumar, K., Nambiar, S. M., & Pathak, R. (2025) · Vaccines · doi:10.3390/vaccines13040424 · Cited by 54
Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
Benkeser, D. C., Fong, Y., Janes, H., Kelly, E. J., Hirsch, I., Sproule, S., Stanley, A. M., Maaske, J., Villafana, T. L., Houchens, C. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00630-0 · Cited by 50
“In both the correlates analyses and Falsey et al., COVID-19 endpoints were included through to March 5, 2021, the data cut date of the primary analysis.”
BackgroundMethodInfluentialSelf-citationLytras, T., Kontopidou, F. V., Lambrou, A., & Tsiodras, S. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27934 · Cited by 40
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
Sutton, N., Ramos, A. S. F., Beales, E. R., Smith, D., Ikram, S., Galiza, E. P., Hsia, Y., & Heath, P. T. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2098719 · Cited by 46
“Four trials of the ChAdOx-1 (Oxford-AstraZeneca) vaccine used 0.9% saline as the control group [16,33,34,36] and two used a MenACWY vaccine [32,35].”
MethodInfluentialAkahata, W., Sekida, T., Nogimori, T., Ode, H., Tamura, T., Kono, K., Kazami, Y., Washizaki, A., Masuta, Y., Suzuki, R., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101134 · Cited by 41
COVID-19 Vaccination in Korea: Past, Present, and the Way Forward
Nham, E., Song, J. Y., Noh, J. Y., Cheong, H. J., & Kim, W. J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e351 · Cited by 45
Bollaerts, K., Wyndham-Thomas, C., Miller, E., Izurieta, H. S., BLACK, S. B., Andrews, N. J., Rubbrecht, M., Heuverswyn, F. V., & Neels, P. (2024) · Biologicals · doi:10.1016/j.biologicals.2024.101750 · Cited by 44
Li, G., Cappuccini, F., Marchevsky, N. G., Aley, P. K., Aley, R., Anslow, R., Bibi, S., Cathie, K., Clutterbuck, E., Faust, S. N., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(22)00770-x · Cited by 44
Pascuale, C. A., Varese, A., Ojeda, D. S., Pasinovich, M., López, L., Rossi, A. H., Rodríguez, P. E., Miglietta, E. A., Mazzitelli, I. G., García, F. D. D., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100706 · Cited by 44
“14 The use of heterologous vaccination schedules in Argentina has been shown to be an adequate strategy in order to accelerate the rate of vaccination.”
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 47
Eugenia-Toledo-Romaní, M., Verdecia-Sánchez, L., Rodríguez-González, M., Rodríguez-Noda, L., Valenzuela‐Silva, C., Paredes-Moreno, B., Sánchez-Ramírez, B., Pérez-Nicado, R., González-Mugica, R., Hernández-García, T., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.082 · Cited by 42
van Doremalen, N., Avanzato, V. A., Goldin, K., Feldmann, F., Schulz, J. E., Haddock, E., Okumura, A., Lovaglio, J., Hanley, P. W., Cordova, K., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00592-9 · Cited by 46
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials
Lora, A. J. M., Long, J. E., Huang, Y., Baden, L. R., Sahly, H. M. E., Follmann, D. A., Goepfert, P., Gray, G., Grinsztejn, B. G. J., Kotloff, K. L., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.51974 · Cited by 42
Self-citationProphylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 56
Schmidt, P., Narayan, K. M., Li, Y., Kaku, C. I., Brown, M. E., Champney, E. R., Geoghegan, J. C., Vásquez, M., Krauland, E. M., Yockachonis, T. J., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adg2783 · Cited by 36
“trials and/or real-world vaccine effectiveness studies (23-37) (Table S6).”
BackgroundMethodVariants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 43
“5% in participants age 65 years and older [140] Preventing the onset of symptomatic and severe coronavirus disease 2019 (COVID-19) 15 days or more after the second dose in adults, including older adults Two doses”
BackgroundRSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing
Wilkins, D. E., Hamrén, U. W., Chang, Y., Clegg, L. E., Domachowske, J. B., Englund, J. A., Muller, W. J., Leach, A. J., Kelly, E. J., & Villafana, T. L. (2024) · PEDIATRICS · doi:10.1542/peds.2024-067174 · Cited by 46
Self-citationLi, Z., Liu, S., Li, F., Li, Y., Li, Y., Peng, P., Li, S., Li, H., & Liu, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965971 · Cited by 44
“…II/III, 31, double-blind 58.4% (−73.4, 92.9)† Ella 2021* (53) BBV152 vaccine 2, 28 d, 6 µg ≥ 60 893/965 Indian III, 25, double-blind 67.8% (8.0, 90.0) Falsey 2021 (54) ChAdOx1-S(AZD1222) 2, 28 d, 5 × 1010 VP ≥ 65 3696/1812 the United States, Chile, Peru III, 88, double-blind 83.5% (54.2,…”
InfluentialAkinosoglou, K., Rigopoulos, E. A., Kaiafa, G. D., Daios, S., Karlafti, E., Ztriva, E., Polychronopoulos, G., Gogos, C. A., & Savopoulos, C. G. (2022) · Viruses · doi:10.3390/v15010118 · Cited by 39
“No effect of AZD7442 on antibody responses following AZD 1222 COVID-19 vaccinations in humans was observed [39,40].”
BackgroundTherapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
Pao, S.-C., Chu, M.-T., & Chung, W. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040867 · Cited by 51
“Compared to other virus-based vectors, adenoviral vectors have less potential genotoxicity and have been applied to infectious diseases such as COVID-19 [82], Ebola virus [83], and malaria [84].”
BackgroundVLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 39
COVID-19 in Latin America: A Snapshot in Time and the Road Ahead
LaRotta, J., Escobar, O., Avila-Aguero, M. L., Torres, J. P., de Almeida, R. S., Morales, G. D. C., & Srivastava, A. K. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00748-z · Cited by 49
Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review
Abolmaali, M., Rezania, F., Behnagh, A. K., Hamidabad, N. M., Gorji, A., & Mirzaasgari, Z. (2022) · Immunologic Research · doi:10.1007/s12026-022-09316-6 · Cited by 38
Benn, C. S., Schaltz‐Buchholzer, F., Nielsen, S., Netea, M. G., & Aaby, P. (2023) · iScience · doi:10.1016/j.isci.2023.106733 · Cited by 50
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Heitmann, J. S., Tandler, C., Marconato, M., Nelde, A., Habibzada, T., Rittig, S. M., Tegeler, C. M., Maringer, Y., Jaeger, S. U., Denk, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40758-0 · Cited by 38
Okuyama, R. (2023) · Vaccines · doi:10.3390/vaccines11121737 · Cited by 47
Sobieszczyk, M. E., Maaske, J., Falsey, A. R., Sproule, S., Robb, M. L., Frenck, R. W., Tieu, H., Mayer, K. H., Corey, L., Neuzil, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160565 · Cited by 36
“These included a multiple imputation approach for missing outcomes due to censoring or other reasons for truncated follow-up, an IPCW approach, and a multicovariate analysis using the primary analysis model (8).”
InfluentialSelf-citationSaunders, J. E., Gilbride, C., Dowall, S., Morris, S. J., Ulaszewska, M., Spencer, A. J., Rayner, E. L., Graham, V., Kennedy, E., Thomas, K. M., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104523 · Cited by 37
Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 32
Deng, L., Glover, C., Dymock, M., Pillsbury, A., Marsh, J., Quinn, H., Leeb, A., Cashman, P. M., Snelling, T., Wood, N., et al. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51619 · Cited by 33
An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19)
Bahrami, A. A., Azargoonjahromi, A., Sadraei, S., Aarabi, A., Payandeh, Z., & Rajabibazl, M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00339-3 · Cited by 33
Asano, M., Okada, H., Itoh, Y., Hirata, H., Ishikawa, K., Yoshida, E., Matsui, A., Kelly, E. J., Shoemaker, K., Olsson, U., et al. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.030 · Cited by 34
Self-citationInterspecies Jumping of Bat Coronaviruses
Wong, A. C. P., Lau, S. K. P., & Woo, P. C. Y. (2021) · Viruses · doi:10.3390/v13112188 · Cited by 36
Metadata
- Authors
- Falsey, A. R., Sobieszczyk, M. E., Hirsch, I., Sproule, S., Robb, M. L., Corey, L., Neuzil, K. M., Hahn, W., Hunt, J., Mulligan, M. J., McEvoy, C., DeJesus, E., Hassman, M., Little, S. J., Pahud, B. A., Durbin, A., Pickrell, P., Daar, E. S., Bush, L., Solis, J., Carr, Q. O., Oyedele, T., Buchbinder, S., Cowden, J., Vargas, S. L., Guerreros Benavides, A., Call, R., Keefer, M. C., Kirkpatrick, B. D., Pullman, J., Tong, T., Brewinski Isaacs, M., Benkeser, D., Janes, H. E., Nason, M. C., Green, J. A., Kelly, E. J., Maaske, J., Mueller, N., Shoemaker, K., Takas, T., Marshall, R. P., Pangalos, M. N., Villafana, T., & Gonzalez-Lopez, A.
- Affiliations
- Columbia University Irving Medical Center (US)
- From the University of Rochester School of Medicine and Dentistry (A.R.F., M.C.K.) and Rochester Regional Health (A.R.F.), Rochester, and Vagelos College of Physicians and Surgeons, New York Presbyterian Columbia University Irving Medical Center, Department of Medicine, Division of Infectious Diseases (M.E.S.) and the New York University Vaccine Center (M.J.M.), New York — all in New York; Biometrics (I.H.) and Infectious Diseases (J.A.G.), Late-Stage Development, Respiratory and Immunology (R.P.M.), Biopharmaceuticals Research and Development (M.N.P.), AstraZeneca, Cambridge, United Kingdom; Biometrics (S.S., K.S.) and Infectious Diseases, Late-Stage Development, Respiratory and Immunology (J.M., T. Takas, T.V., A.G.-L.), Translational Medicine, Microbial Sciences, Biopharmaceuticals Research and Development (E.J.K.), and Clinical Development, Early Global Development, Oncology Research and Development (N.M.), AstraZeneca, Gaithersburg, the Walter Reed Army Institute of Research, Silver Spring (M.L.R.), t...
- Corresponding author
- Villafana, Tonya
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2348-2360
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8522798
- OpenAlex
- W3202234535
- Cited by
- 670
- References
- 21
- Citations by year
- 2026: 33 · 2025: 72 · 2024: 97 · 2023: 185 · 2022: 259 · 2021: 24
- FWCI
- 44.70
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- United States Government (Agreement No. W15QKN-20-9-1003)
- National Institute of Allergy and Infectious Diseases (UM1 AI 148372, UM1 AI 148450, UM1 AI 148574, UM1 AI 148684, UM1 AI 148684-03, UM1 AI 68614HVTN, UM1 AI 68618, UM1 AI 68619, UM1 AI 68635, UM1 AI 68636)
- Biomedical Advanced Research and Development Authority (W15QKN-21-9-1003)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- ChAdOx1 nCoV-19 vaccine, COVID-19 vaccines, SARS-CoV-2, vaccine efficacy, vaccine safety, immunogenicity, neutralizing antibodies, nucleocapsid antibodies, older adults, adverse events
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, SARS-CoV-2, Vaccine Efficacy, ChAdOx1 nCoV-19, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Chile, Double-Blind Method, Female, Humans, Male, Middle Aged, Peru, United States, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.